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Statins are known to lessen the severity of renal
ischemia-reperfusion injury. The present study was
undertaken to define the mechanism of renoprotective
actions of statins using a mouse kidney injury model.
Treatment of mice with pravastatin, a widely used statin,
improved renal function after renal ischemia-reperfusion
without lowering the plasma cholesterol level.
Administration of pravastatin with mevalonate, a product
of HMG-CoA reductase, eliminated renal protection
suggesting an effect of pravastatin on mevalonate or its
metabolism. In hypercholestrolemic apolipoprotein E
knockout mice with reduced HMG-CoA reductase activity;
the degree of injury was less severe than in control mice,
however, there was no protective action of pravastatin
on renal injury in the knockout mice. Treatment with a
farnesyltransferase inhibitor (L-744832) mimicked
pravastatin’s protective effect but co-administration with
the statin provided no additional protection. Both pravastatin
and L-744832 inhibited the injury-induced increase in
plasma IL-6 concentration to a similar extent. Our results
suggest the protective effect of pravastatin on renal
ischemia-reperfusion injury is mediated by inhibition of the
mevalonate-isoprenoid pathway independent of its lipid
lowering action.
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Acute kidney injury (AKI), previously referred to as acute
renal failure, is a common clinical syndrome resulting from a
rapid reduction of glomerular filtration rate. AKI has been
reported to occur in approximately 5% of hospitalized
patients and 30–50% of patients in intensive care units.
Despite the significant improvements in supportive care,
the mortality and morbidity associated with AKI continue to
be alarmingly high over the past three decades.1–3 A major
reason for this is a lack of specific pharmacological inter-
ventions against AKI.1
The mevalonate pathway mediates the sequential bio-
chemical reactions leading to the synthesis of cholesterol.4,5
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, statins, block the conversion of
HMG-CoA to mevalonate, which is a rate-determining step
in the mevalonate pathway, resulting in decreased cholesterol
production.6 As hyperlipidemia causes tissue injury through
direct toxic effects of lipids on cells and a formation of
intratissue atherosclerosis, statins are widely used to lower
plasma cholesterol levels in hyperlipidemic patients.5,7–10
Blocking cholesterol synthesis was thought to be the primary
statins’ mechanism of action. However, reports about plasma
cholesterol-independent tissue-protective effects of statins
have been increasing, and it is now recognized that statins
have clinical benefits that appear to be greater than those one
would expect from improving the lipid profile alone.5,8–12
The plasma cholesterol-independent tissue-protective effects
of statins are thought to be mediated by their immuno-
modulatory and anti-inflammatory effects that relate to
statin’s ability to block the synthesis of important inter-
mediate products, including the isoprenoids in the mevalo-
nate pathway.5,13–15
Renal ischemia–reperfusion (I/R) injury is an important
cause for AKI. There is growing evidence that intrarenal
inflammation is involved in renal I/R injury using in vitro
and in vivo models, and therefore intrarenal inflammation is
an attractive target for the development of drug therapies for
AKI.16–18 Given that statins have immunomodulatory effects,
they would be expected to protect against renal I/R injury.
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Thus far, several groups have tested the protective effects
of statins, including pravastatin,19 cerivastatin,20,21 and
atorvastatin,22 on experimental renal I/R injury, and these
data have consistently shown that statins improve the course
of the injury. However, it is not yet clear whether the
protective action of statins on renal I/R injury is mediated
by their lipid-lowering action or the inhibition of the
mevalonate pathway in any in vivo studies.
To clarify the mechanism of statin’s action in vivo, this
study examined the effect of mevalonate on the protective
effect of pravastatin from renal I/R injury using a mouse
model. The renoprotective effect of pravastatin was also
evaluated using apolipoprotein E-deficient mice (ApoE/)
that is known to exhibit hypercholesterolemia.23,24 Further-
more, to dissect further the mechanism of statin’s renopro-
tection, we examined whether prenylation inhibitors,
including L-744832 and GGTI-2133, protected mice against
renal I/R injury. Our results indicate that the protective effect
of pravastatin on renal I/R injury is dependent on the
mevalonate–isoprenoid pathway, but independent of its
lipid-lowering action.
RESULTS
Effect of pravastatin on renal I/R
First, we confirmed the protective effect of pravastatin on
renal I/R injury. The mice were divided into three groups.
Control group was treated with vehicle, low-dose group was
given 50 mg per kg body weight of pravastatin and high-dose
group was given 150 mg per kg body weight of pravastatin. As
shown in Figure 1a, although no significant effect was
observed in the low-dose group at any time points and in the
high-dose group at 48 and 72 h after I/R, plasma creatinine
level of the high-dose group was significantly lower than the
control group at 24 h after I/R. Histopathological analysis
with periodical acid-Schiff (PAS) staining revealed that
I/R caused cast formation in tubules, tubular dilatation, and
leukocyte infiltration in the outer medulla (Figure 1b).
Pravastatin ameliorated these pathological changes (Figure 1c).
As the histopathological changes were semiquantified by the
measurement of PAS-positive area (Figure 1d), the improve-
ment by pravastatin was dose dependent. These data clearly
collaborated with the previous observation that pravastatin had
protective effect in a rat renal I/R model.19
Effect of mevalonate on renal I/R
Next, we studied the effect of mevalonate, a product of
HMG-CoA reductase, on renal I/R injury. The mice were
divided into four groups: control group (vehicle treatment
and sham operation); mevalonate treatment and sham
operation group; vehicle treatment and I/R group; mevalo-
nate treatment and I/R group. Figure 2 summarizes the data
for plasma total cholesterol and creatinine concentrations.
Mevalonate tended to increase the plasma total cholesterol
in sham-operated mice and significantly increased it in
I/R-operated mice. Approximately 40% of administered
mevalonate has been reported to be eliminated into urine.25
Therefore, this increase in cholesterol may be explained by
the impairment of mevalonate excretion into the urine by I/R
injury, thereby increasing blood mevalonate concentration
with consecutive increase in the cholesterol synthesis in liver.
I/R significantly increased plasma creatinine level at 24 h after
the operation, and this increase was significantly enhanced
by the pretreatment of mice with mevalonate. These raise a
possibility that mevalonate worsens the renal I/R injury.
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Figure 1 | Effect of pravastatin on plasma creatinine
concentration and histology after renal I/R. (a) Pravastatin
(50 or 150 mg/kg) or vehicle was administered for 3 consecutive
days before mice were subjected to renal I/R. Plasma for
creatinine concentration measurement was collected before I/R
(0 h) and 24, 48, and 72 h after I/R. Open circle, open square, and
closed circle indicate vehicle group, 50 mg pravastatin per kg
body weight group, and 150 mg pravastatin per kg body weight
group, respectively. Values are mean±s.e. (N¼ 7–14 per group).
*Po0.05 vs vehicle. PAS staining was performed with kidney
sections 24 h after I/R from mouse treated with (b) vehicle or
(c) 150 mg pravastatin per kg body weight. The outer strip of
outer medulla is shown at the left and the inner strip of outer
medulla is at the right. Bar¼ 50 mm. (d) The PAS-positive area was
measured (see Materials and Methods) in kidney sections 24 h
after I/R from mouse treated with vehicle, 50 mg pravastatin
per kg body weight , or 150 mg pravastatin per kg body weight.
Values are mean±s.e. (N¼ 5–6 per group). *Po0.05 vs vehicle.
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The combined administration of pravastatin and mevalonate
eliminated the protective effect of pravastatin
The effect of mevalonate on the renoprotective action of
pravastatin was examined. The mice were divided into three
groups: control group (both vehicles for pravastatin and
mevalonate treatment); pravastatin and vehicle for mevalo-
nate treatment group; pravastatin and mevalonate treatment
group. Plasma cholesterol levels 24 h after I/R did not differ
between the three groups (Figure 3a). At 24 h after I/R,
plasma creatinine concentration in the pravastatin and
vehicle for mevalonate treatment group was significantly
lower than that in the control group. In contrast, the
protective effect of pravastatin from renal I/R injury was
not observed in the pravastatin and mevalonate treatment
group. These data suggest that the renoprotective effect of
pravastatin is mediated by an inhibition of the mevalonate
pathway.
Effect of hyperlipidemia on renal I/R injury in apolipoprotein
E knockout mice (ApoE/)
Apolipoprotein E knockout mice (ApoE/) have been
reported to exhibit hypercholesterolemia insensitive to statins
and a lower activity of HMG-CoA reductase.23,24,26,27 We
used these mice and evaluated the effect of hyperlipidemia on
renal I/R injury. Mean±s.e. values of the plasma total
cholesterol concentration 24 h after sham operation or
I/R were 78.0±8.5 (sham) and 137.8±33.9 mg/100 ml
(I/R) for the genetic control (C57BL/6J) mice (n¼ 4), and
842.3±129.4 (sham) and 776.5±51.6 mg/100 ml (I/R) for
ApoE/ (n¼ 4), respectively. Mean±s.e. values of the
creatinine concentrations 24 h after sham operation and I/R
were 0.1±0.01 (sham) and 2.1±0.2 mg/100 ml (I/R) for the
control mice, and 0.1±0.01 (sham) and 2.1±0.5 mg/100 ml
(I/R) for ApoE/, respectively. These values were not signi-
ficantly different between the control mice and ApoE/.
Figure 4 shows the results from histopathological analysis
with PAS staining. I/R dramatically caused cast formation in
the control mice, whereas the change in ApoE/ was
somewhat reduced. The PAS-positive area in ApoE/ after
I/R was significantly smaller than that in the control mice.
These data show that hyperlipidemia of ApoE/ does not
worsen the renal I/R injury but seems to rather weaken it.
Effect of pravastatin in ApoE/
We checked the protective effect of pravastatin on renal I/R
injury in ApoE/. Figure 5 summarizes the data for plasma
total cholesterol and creatinine concentrations. In the control
mice, increase in plasma total cholesterol level by renal I/R
was observed. On the contrary, I/R decreased plasma total
cholesterol concentration in ApoE/. These changes in
response to I/R were not affected by the treatment with
pravastatin. The mechanism underlying the I/R-induced
plasma cholesterol changes in both the control mice and
ApoE/ is not clear at present. In the control mice, renal
function after I/R was significantly improved by the
treatment with pravastatin compared with mice treated with
vehicle (Figure 5c). This renal protective action of pravastatin
was not seen in ApoE/ (Figure 5d).
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Figure 2 | Effect of mevlonate on plasma total cholesterol
and creatinine concentrations after renal I/R. Mevalonate
or vehicle was administered 25, 13, and 1 h before sham or
renal I/R operation. (a) Plasma total cholesterol concentration
was measured 24 h after operation and (b) plasma creatinine
concentration was measured before (pre) and 24 h after
operation. Values are mean±s.e. (N¼ 4–5 per group).
**Po0.01 vs vehicle and sham. #Po0.05 vs vehicle and I/R.
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Figure 3 | Effect of mevlonate on renoprotection by
pravastatin. Vehicles for mevalonate and pravastatin, for
mevlonate and pravastatin, or for mevalonate and pravastatin
were administered to mice before I/R as in Figures 1 and 2,
except for the treatment protocol for pravastatin (100 mg/kg/day
for 5 consecutive days before I/R operation). (a) Plasma total
cholesterol concentration was measured 24 h after I/R and
(b) plasma creatinine concentration was measured before (pre)
and 24 h after I/R. Values are mean±s.e. (N¼ 7–8 per group).
*Po0.05 vs vehicles for mevalonate and pravastatin.
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Effects of prenylation inhibitors on renal I/R injury
It is known that the mevalonate pathway regulates the bio-
synthesis of cholesterol as well as isoprenoids including
farnesyl pyrophosphate and geranylgeranyl pyrophosphate.
We thus evaluated the renoprotective effects of L-744832
(farnesyltransferase inhibitior) and GGTI-2133 (geranyl-
geranyl transferase I inhibitior) on renal I/R injury.28,29
L-744832 and GGTI-2133 were administered to mice just
after I/R and plasma creatinine levels were measured 24 h
after I/R (Figure 6a). Serum creatinine level in L-744832
treatment group was significantly lower than that of vehicle
control group (Figure 6a). In contrast, GGTI-2133 had
no significant effect on the increase in plasma creatinine
concentration after I/R.
To examine whether the effect of L-744832 resulted from
the inhibition of the mevalonate pathway, we compared
the effect of treatment with L-744832 alone with that of
combination of L-744832 and pravastatin on I/R-induced
dysfunction in normal mice. As shown in Figure 6b, no
significant additive effect of the coadministration was
observed, indicating that two drugs share the same pathway.
Effects of pravastatin and L-744832 on serum IL-6
concentration after renal I/R
Interleukin-6 is primarily involved in the regulation of
inflammation.30 Furthermore, serum IL-6 level is reported to
increase after renal I/R.31 To confirm whether the pravasta-
tin’s renoprotection is mediated by its anti-inflammatory
effect and L-744832 has a similar effect to pravastatin on
serum IL-6 level or not, we measured serum IL-6 levels 24 h
after I/R in mice treated with pravastatin or L-744832. Serum
IL-6 concentration in mice subjected to I/R was significantly
higher than that in intact mice. When mice were treated with
I/RSham
ApoE–/–
I/RSham
Control
*
0
5000
10,000
15,000
PA
S-
po
sit
ive
 a
re
a
 (µ
m
2 )
I/R
Sham
Control ApoE–/–
Figure 4 | Renal histology after sham or renal I/R operation
in the genetic control mice and ApoE/. PAS staining was
performed with kidney sections from the genetic control mice
(a) before and (b) 24 h after renal I/R. Similarly, kidney sections
from ApoE/ (c) before and (d) 24 h after renal I/R were stained
with PAS. Bar¼ 50 mm. (e) The PAS-positive area was measured
in kidneys from the genetic control mice and ApoE/. Values
are mean±s.e. (N¼ 4 per group). *Po0.05 vs control with I/R.
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Figure 5 | Effect of pravastatin on plasma total cholesterol
and creatinine concentrations after renal I/R in the genetic
control mice and ApoE/. Pravastatin (100 mg/kg) or vehicle
was administered to the (a and c) genetic control mice and
(b and d) ApoE/ for 5 consecutive days before I/R. Plasma
for measurements of (a and b) total cholesterol and (c and d)
creatinine concentrations was collected before I/R (Pre) and
24 h after I/R. Values are mean±s.e. (N¼ 5 per group).
*Po0.01 vs vehicle with I/R.
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pravastatin or L-744832, significantly lower serum IL-6 levels
were observed compared with that in mice treated with
vehicle (Figure 7).
DISCUSSION
This study clearly showed that pravastatin, a widely used
statin, protected normal mice from renal I/R injury without
any reduction in plasma cholesterol level. This renoprotective
effect of pravastatin was diminished by the coadministration
of mevalonate with pravastatin. When we used ApoE/
that had a 10-times higher plasma total cholesterol
concentration compared with that of their genetic control
and had been shown to exhibit a reduced activity of HMG-
CoA reductase,23,24 pravastatin had no effect on renal I/R
injury. Treatment with mevalonate alone worsened the degree
of renal I/R injury. Treatment with L-744832, an isoprenyl-
ation inhibitor, significantly ameliorated renal dysfunction
after I/R. The combination of pravastatin and L-744832 did
not further improve renal dysfunction after I/R, compared
with treatment with L-744832 alone. Pravastatin as well as
L-744832 inhibited I/R-induced increase in plasma IL-6
concentration to a similar extent. Together, these data
strongly suggest that the inhibition of the mevalonate–
isoprenoid pathway, which leads to anti-inflammation, is
important for the renoprotective action of pravastatin.
Moreover, the lipid-lowering action of pravastatin is unlikely
to be related to its protective effect on renal I/R injury.
Biologically important products other than cholesterol in
the mevalonate pathway are dolichols, ubiquinone, and the
isoprenoids, including farnesyl pyrophosphate and geranyl-
geranyl pyrophosphate.4,5 Isoprenoids are known to play
an important role in the post-translational modification
of G proteins such as Ras, Rho, and Rab, for their proper
intracellular localization.5,13 The protein isoprenylation
reaction is catalyzed by farnesyl or geranylgeranyl transferase.
In this study, the treatment with L-744832, a farnesyl trans-
ferase inhibitor,28 significantly improved the renal deficit
after I/R. On the other hand, GGTI-2133, a geranylgeranyl
transferase I inhibitor,29 had not significant effect on renal
I/R injury. Recently, chaetomellic acid A, a farnesyltransferase
inhibitor, was also reported to produce protection against
I/R-induced renal dysfunction.32 These data suggest that
protein farnesylation is involved in pathobiology of renal
I/R injury, and this leads to the development of specific
pharmacological interventions.
We demonstrate here that serum IL-6 level was signifi-
cantly increased after renal I/R, and this increase was
prevented by pravastatin or L-744832 treatment. IL-6 is a
pleiotropic cytokine and a major regulator of inflamma-
tion.30 Growing evidence suggests that IL-6 is a critical
contributor to renal I/R injury. In IL-6 knockout mice, the
degree of renal I/R injury was less severe compared with that
of the genetic control mice.30 Normal mice administered a
monoclonal antibody against IL-6 were resistant to renal I/R
injury.30,31 Increased production of IL-6 in the ischemic
kidney originated largely from macrophages that infiltrated
into the outer medulla.31 Resistance of IL-6 knockout mice to
renal I/R injury was reduced by the reconstitution of IL-6
knockout mice with bone marrow from wild-type mice.31
Moreover, a genetic heme oxygenase-1 deficiency in mice
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Figure 6 | Effects of prenylation inhibitors on I/R-induced renal
dysfunction. (a) L-744832 (40 mg/kg), its vehicle (saline),
GGTI2133 (40 mg/kg), or its vehicle (dimethyl sulfoxide) was
intraperitoneally administered to mice just after renal I/R.
(b) L-744832 and vehicle for pravastatin or L-744832 and
pravastatin were administered to mice as in Figures 5 and 6a.
Plasma for creatinine concentration measurement was
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Figure 7 | Effect of pravastatin or L-744832 on renal
I/R-induced serum IL-6 elevation. Vehicle for pravastatin
and vehicle for L-744832 (vehicle), pravastatin and vehicle for
L-744832 (pravastatin), or vehicle for pravastatin and L-744832
(L-744832) were administered to mice (pravastatin, 100 mg/kg/
day, 5 consecutive days before I/R operation; L-744832, 40 mg/kg,
just after I/R operation). Plasma IL-6 concentration was measured
24 h after I/R. Plasma IL-6 concentration from intact control mice
(intact) was also measured. Values are mean±s.e. (N¼ 6–8 per
group). *Po0.05, **Po0.01 vs vehicle.
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increased the sensitivity to renal I/R injury, and this increase
was lowered by the treatment of mice with a monoclonal
antibody against IL-6.33 Hence, the renoprotective effects
of paravastatin and L-744832 against I/R injury may be
mediated through the suppression of IL-6 production. We
note that Xue et al.34 recently reported that pretreatment
with tipifarnib, a farnesyl transferase inhibitor, resulted in a
significant inhibition of IL-6 production in a murine model
of LPS-induced inflammation.
In this study, pravastatin and L-744832 could not
completely protect mice against renal I/R injury. Similar
partial effects of other statins including cerivastatin and
atorvastatin on renal I/R injury have been reported.20–22
Although the exact reason for the insufficient effect of statins
is not clear at present, this might be explained by an inhi-
bitory activity of statins on a mammalian target of rapamycin
(mTOR) pathway. Recently, Finlay et al.35 observed that
atorvastatin could inhibit the mTOR pathway. An inhibition
of the mTOR pathway by sirolimus has been shown to
contribute to the development of renal I/R injury.36,37
Therefore, decrease in the mTOR response as a consequence
of statin treatment may partially mask statin’s beneficial
effect on renal I/R injury. Alternatively, a complicated role of
nitric oxide (NO) in the pathobiology of renal I/R injury may
explain the partial effect of statin on renal I/R injury. Statin
is known to increase NO production that is mediated
by inhibiting isoprenylation of Rho.5,13 It has been observed
that NO can either ameliorate or exacerbate renal injury
depending on the origin, site, and rate of production and
its chemical fate.38 Therefore, it is possible that improper
production of NO by statins leads to the exacerbation of
renal I/R injury. The detailed molecular mechanisms of
partial effect of statins on renal I/R injury await clarification
in future studies.
When we used ApoE/, renal function after I/R was
comparable to those of the control mice. Similarly, Buzello
et al. have reported that the degree of nephrectomy-induced
renal injury is not so severe in ApoE/, compared with that
of the genetic control mice.39 Furthermore, 3 weeks after
renal I/R, kidney functions of rats fed with a cholesterol-
supplemented diet for 3 weeks before I/R was similar to those
of rats fed with a regular diet.40 Although dyslipidemia has
been suggested to accelerate the progression of chronic
kidney disease,41 these data indicate that dyslipidemia does
not appear to worsen the AKI.
A series of experiments done by Zager et al.42,43 have
revealed that renal I/R induces cholesterol accumulation in
the kidney cortex including proximal tubules that is suscepti-
ble to I/R injury, and this accumulation contributes to the so-
called ‘cytoresistant state’ (renal resistance to additional
ischemic damage). The mechanism underlying ‘cytoresistant
state’ is thought to be an increase in plasma membrane
rigidity, which lessens membrane rupture during the evolu-
tion of necrotic cell death.44 In this study, although we did
not see significant difference in renal function in between the
control mice and ApoE/, less severe histopathological
changes in ApoE/ post I/R was observed. This observa-
tion might result from ‘cytoresistant state’ induced by hyper-
lipidemia in ApoE/. Alternatively, as ApoE/ has
a reduced activity of HMG-CoA reductase,23,24 a less produc-
tion of intermediate products in the mevalonate pathway
after renal I/R may contribute to the resistance of ApoE/
to renal I/R injury.
Simvastatin, one of clinically used statin, has been
reported to attenuate cardiac I/R injury in ApoE/.26 In
contrast, we failed to observe the protective effect of
pravastatin on renal I/R injury in ApoE/ and interpreted
the lack of the effect on their reduced HMG-CoA reductase
activity. The reason for the apparent loss in potency of
pravastatin compared with that of simvastatin is not clear at
present. Tissue-dependent effect of statins is one possibility.
Other possible explanation for this is that simvastatin
could have additional effects other than the inhibition
of HMG-CoA reductase. In fact, it has been reported that
simvastatin, but not pravastatin, binds to the inserted
domain of leukocyte function antigen (LFA)-1 and prevents
the function of LFA-1.45 This effect was independent of
inhibition of HMG-CoA reductase.45 It is important to note
that inhibition of LFA-1 by monoclonal antibodies specific
for the antigen has been shown to be effective in animal
models for renal I/R injury.46
In this study, we administered pravastatin to mice with a
dose of 100 or 150 mg/kg. These doses were higher than daily
therapeutic dose in humans (20–80 mg/kg/day). But the dose
for mice is not extremely high because, when these doses
were given to rodents, serum concentration of pravastatin
was equivalent to those in humans.6,47 This species difference
might be explained by more rapid metabolism from
circulation in rodents.48 In addition, we did not observe
serious adverse effects after the administration of such high
doses of pravastatin to mice (unpublished data). Therefore,
it is unlikely that clinically irrelevant blood concentration of
pravastatin causes renoprotection from I/R injury observed
in this study.
Pravastatin is unique among statins in that it is hydro-
philic and is the only statin that is selectively taken up into
hepatocytes, thereby efficiently inhibiting liver HMG-CoA
reductase with minimal inhibition of the enzyme in other
tissues such as skeletal muscle.6,49 Therefore, myositis
and rhabdomyolysis are scarcely seen in patients treated
with pravastatin. Furthermore, a single-dose study demon-
strated that pravastatin pharmacokinetics was not affected
in patients with renal impairment50 and there was no
accumulation of pravastatin or its metabolites over an
interdialytic interval in hemodialysis patients when adminis-
tered with a usual clinical dose.51 Based on these, pravastatin
can be safely administered with a usual dose to patients with
renal failure. Our study clearly showed that pravastatin had
the potential to be effective in renal I/R injury. These features
indicate that pravastatin would be an attractive drug against
AKI. To this end, we need further clinical evaluations in
humans.
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MATERIALS AND METHODS
Animals
All animal studies were in accordance with Guide for the Care and
Use of Laboratory Animals in University of Miyazaki and SOP for
the experimental animals of Daiichi-Sankyo Co., Ltd. and were
conducted in compliance with Law Concerning the Protection and
Control of Animals (Japanese Law No. 105, October 1, 1973, revised
on June 22, 2005), Standards Relating to the Care and Management
of Laboratory Animals and Relief of Pain (Notification No.88 of the
Ministry of the Environment, Japan, April 28, 2006) and Guidelines
for Animal Experimentation (the Japanese Association for Labora-
tory Animal Science, May 22, 1987).
Male ddy mice (ddy) were purchased from Japan SLC Inc.
(Shizuoka, Japan). Male apolipoprotein E knockout mice (ApoE/)
originated from the Jackson laboratory (Bar Harbor, ME, USA) were
breaded in our laboratory. Male C57BL/6J mice were purchased from
Clea Japan Inc. (Tokyo, Japan) as control mice for the ApoE/.
Renal ischemia–reperfusion (I/R) injury
In this study, an established mouse model of renal ischemia–
reperfusion was used as described previously. Mice (25–35 g) were
anesthetized with pentobarbital (65–75 mg/kg) and underwent
abdominal incision and dissection of the bilateral renal pedicles. A
microvascular clamp (Roboz, Gaithersburg, MD, USA) was placed
on each renal pedicle for 30 min for ddy mice, and for 20 min for
both ApoE/ and its wild type of C57BL/6J mice, respectively.
After ischemia period, the clamps were removed, the wound was
sutured, and animals were allowed to recover. The animals were kept
at constant body temperature with continuous monitoring during
ischemia–reperfusion period, and warmed physiological saline was
given to maintain the body fluid volume just after being clamped
and before being sutured.
Reagents and administration regimen
Pravastatin sodium was generously donated by Daiichi-Sankyo Co., Ltd.
(Tokyo, Japan). Mevalonolactone was from Sigma Chemical Co.
(St Louis, MO, USA). L-744832 and GGTI-2133 were from Calbiochem
(San Diego, CA, USA). Pravastatin, mevalonolacton, and L-744832 were
dissolved in physiological saline. GGTI-2133 was dissolved in dimethyl
sulfoxide. Pravastatin was administered orally by gavage. Mevalonate,
L-744832, and GGTI-2133 were administered intraperitoneally.
Pravastatin was administered to ddy mice for 3 or 5 consecutive
days before I/R at a dosage level of 50, 100, or 150 mg/kg. Meva-
lonate (20 mg/kg) was consecutively administered to ddy mice at 25,
13, and 1 h before I/R. Pravastatin was administered to ApoE/
and its control (C57BL/6J) mice at a dosage level of 100 mg/kg for 5
consecutive days before I/R. The control group was administered
physiological saline in the same manner. L-744832 and GGTI-2133
were administered to C57BL/6J mice at a dose of 40 mg/kg before
closing the peritoneum. The vehicle control groups for L-744832
and GGTI-2133 were administered physiological saline or dimethyl
sulfoxide, respectively, in the same manner.
Blood chemical analysis and histopathological evaluation
Blood samples for chemical analysis were obtained from tail blood
vessel or inferior vena cava under ether anesthesia condition. Plasma
creatinine level was measured by the commercial assay kit Liquitec
creatinine PAP II (Roche, Basel) or an autoanalyzer (FUJIDRI-
CHEM: Fuji Film Medical Co., Ltd. Tokyo, Japan; TBA-200FR:
Toshiba Medical Systems Co., Ltd., Tokyo, Japan). Plasma total
cholesterol level was also measured by an autoanalyzer.
Serum IL-6 concentration was measured using the Bio-Plex
Mouse Cytokine Panel (Bio-Rad Laboratories Inc., Tokyo, Japan).
IL-6 concentration was calculated by Bio-Plex Manager 4.0 software
using a standard curve derived from a known concentration of
a recombinant IL-6 solution.
For the histopathological evaluation, the left kidney was removed
at indicated time points and fixed in 10 % (v/v) neutral-buffered
formalin. Serial sections of 2 mm thickness were stained with PAS.
The semiquantitative analysis was performed by measuring the area
of PAS-positive hyaline cast in the renal tubules of the inner stripe of
the outer medulla. Twelve microscope fields (75,436 mm2 per field)
were scanned in each mouse using an image-processing apparatus
(IPAP-WIN, Sumika Technoservice Corporation, Osaka, Japan).
Statistical analysis
Data are expressed as mean±s.e.m. values. Statistical comparisons
of the mean values between two groups were performed using
Student’s t-test; Dunnett’s method was used to test comparisons of
the means between three or more groups. A paired t-test was used
for comparisons within groups. Significant differences were accepted
at Po0.05 and Po0.01.
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